Clinical Trial Update: HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial update on HTMC0435 combined with Temozolomide for recurrent extensive-stage small cell lung cancer, with current status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• HTMC0435 (HTMC0435)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Conditions: Recurrent Extensive Stage Small Cell Lung Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN